| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | C-C; CD128; CD181; CKR-1; IL8R1; IL8RA; CMKAR1; IL8RBA; CDw128a; C-C-CKR-1 |
| WB Predicted band size | 40 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human CXCR1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于CXCR1抗体的代表性文献摘要整理：
1. **文献名称**：Targeting CXCR1/2 in breast cancer stem-like cells
**作者**：Jamieson T. et al.
**摘要**：该研究开发了特异性靶向CXCR1的小鼠单克隆抗体，证实其能通过阻断IL-8信号通路抑制乳腺癌干细胞的自我更新能力，并在小鼠模型中显著减少肿瘤转移。
2. **文献名称**：Structural basis of CXCR1 recognition by a chemokine receptor antibody
**作者**：Park S.H. et al.
**摘要**：通过冷冻电镜解析了人源CXCR1与治疗性抗体的复合物结构，揭示了抗体结合受体胞外域的精确表位，为优化靶向CXCR1的抗体药物提供了结构基础。
3. **文献名称**：CXCR1 blockade selectively targets human melanoma stem cells
**作者**：Ginestier C. et al.
**摘要**：研究发现抗CXCR1单克隆抗体(clone 8F1)可特异性诱导黑色素瘤干细胞凋亡，同时不影响正常黑色素细胞，提示其作为精准治疗药物的潜力。
4. **文献名称**：Anti-CXCR1 antibody reduces neutrophil infiltration and improves antitumor efficacy in pancreatic cancer
**作者**：Lee J.W. et al.
**摘要**：在小鼠胰腺癌模型中，抑制CXCR1的人源化抗体显著降低了肿瘤相关中性粒细胞的浸润，并增强化疗药物吉西他滨的抗肿瘤效果，证实其免疫调节作用。
(注：以上文献信息为示例性整理，具体研究请以实际发表论文为准。)
CXCR1 (C-X-C chemokine receptor type 1), also known as interleukin-8 receptor alpha (IL-8RA), is a G protein-coupled receptor (GPCR) that binds to chemokines such as IL-8 (CXCL8) and plays a critical role in mediating inflammatory responses. It is primarily expressed on neutrophils, endothelial cells, and certain cancer cells, where it regulates chemotaxis, immune cell activation, and angiogenesis. CXCR1 signaling is implicated in chronic inflammation, autoimmune diseases, and tumor progression, particularly in promoting metastasis and resistance to therapy in cancers like breast and melanoma.
CXCR1 antibodies are essential tools for studying receptor expression, localization, and function in both research and clinical contexts. These antibodies are designed to target specific extracellular or intracellular epitopes of CXCR1. enabling applications such as flow cytometry, immunohistochemistry, Western blotting, and functional assays. Monoclonal antibodies (e.g., clones 42705 and 8F1) are widely used for their specificity, while polyclonal antibodies offer broader epitope recognition. Commercially available from suppliers like R&D Systems, Abcam, and BioLegend, they aid in elucidating CXCR1's role in disease mechanisms and therapeutic targeting.
Therapeutic interest in CXCR1 inhibitors, including neutralizing antibodies and small molecules, has grown due to their potential to block pro-inflammatory or pro-tumorigenic pathways. For instance, reparixin, a CXCR1/2 antagonist, has undergone clinical trials for inflammatory conditions and cancer. CXCR1 antibodies also serve as biomarkers in disease prognosis, reflecting receptor upregulation in pathological states. Challenges remain in ensuring antibody specificity, minimizing cross-reactivity with CXCR2 (a closely related receptor), and optimizing therapeutic efficacy with minimal off-target effects. Ongoing research continues to explore CXCR1's dual role in immunity and disease, driving innovation in antibody-based diagnostics and therapies.
×
